Promedior Announces Presentation of Preclinical Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppressed Fibrosis, Neovascularization, and Vascular Leakage
5/7/2012 9:53:44 AM
MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that data from preclinical studies of Pentraxin-2 (PTX-2) were presented yesterday at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. In a poster entitled “Recombinant Pentraxin-2 (rPTX-2) Shifts Macrophage Phenotype, Suppresses Subretinal NV, and Reduces Associated Vascular Leakage and Collagen Deposition”, Promedior and collaborators from The Johns Hopkins University Wilmer Eye Institute highlighted the efficacy and utility of Pentraxin-2 in suppressing fibrosis, neovascularization and vascular leak in independent models of age-related macular degeneration (AMD) and diabetic retinopathy.
comments powered by